CGTN
11.6.2020 05:37:05 CEST | Business Wire | Press release
China’s centralized and efficient command system formed a strong guarantee for the country to win the all-out people's war against COVID-19, according to a recently-released government white paper.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200610005922/en/
The document released on June 7 chronicled China's battle against COVID-19, detailing its painstaking yet effective efforts to control the outbreak domestically and its swift responses to contain the spread globally.
The coronavirus caught China unaware, the white paper noted, but the Chinese government acted swiftly to fight the virus and provide medical treatment for patients, prioritizing people's lives and health.
Since the first cases were detected in late December 2019, China has adopted thorough, rigorous and comprehensive prevention and control measures, as well as enforced quarantine and isolation, on a scale never seen before.
Medical resources have been mobilized across the country, and all those in need have been tested, quarantined, hospitalized or treated. With these measures in place, the country was able to contain the outbreak quickly and prevent a wider spread.
The white paper divides China's fight against the epidemic into five stages – "swift response" (December 27, 2019 to January 19, 2020), "initial containment" (January 20 to February 20), "single-digit increase in new domestic cases" (February 21 to March 17), "initial victory in a critical battle" (March 18 to April 28) and "epidemic control, new normal" (from April 29 onwards).
Timeline: China's fight against COVID-19 in five stages
Graphics: Inside China's all-out effort to contain the coronavirus
It took China more than three months to declare an initial victory in the COVID-19 battle, according to the white paper. This was possible as a result of the country's centralized and highly efficient command system, the white paper concluded.
Under the strong leadership of the CPC Central Committee with Xi Jinping at its core, central authorities exercise overall command while local authorities and all sectors follow the leadership and instructions of the central authorities, perform their respective duties and cooperate with each other.
President Xi assumed full command over the control efforts from the beginning of the outbreak. He chaired 14 meetings of the Standing Committee of the Political Bureau of the CPC Central Committee, four meetings of the Political Bureau, meetings of the Central Commission for Law-based Governance, Central Cyberspace Affairs Commission, Central Commission for Further Reform, and Central Commission for Foreign Affairs, and a meeting with prominent non-CPC figures. At these meetings, he heard briefings about epidemic prevention and control work and made decisions on overall plans for strengthening control efforts and international cooperation.
The president inspected community response and COVID-19 research in Beijing, and visited Wuhan to guide the frontline response. He has also inspected Zhejiang, Shaanxi, Shanxi and Gansu provinces, where he was briefed on progress in coordinating epidemic prevention and control with economic and social development, as well as in poverty alleviation.
Meanwhile, the central government coordinated the epidemic control work. Premier Li Keqiang, as head of the Central Leading Group for Novel Coronavirus Prevention and Control, chaired more than 30 meetings regarding COVID-19 control and economic resumption.
On January 7, Xi issued instructions on epidemic prevention and control work when he chaired a meeting of the Standing Committee of the Political Bureau of the CPC Central Committee.
On January 23, Wuhan, a megacity with a population of more than 10 million, was locked down in an unprecedented effort to contain the spread of the virus.
The central government mobilized medical experts and supplies as well as provisions for daily living needs such as food and energy to assist Wuhan and Hubei, and major public health emergency responses were activated across the country.
On January 25, the Standing Committee of the Political Bureau of the CPC Central Committee set up a central leading group on the epidemic, dispatched a central guiding team and demanded a State Council inter-agency task force play a full role in coordination.
The central leading group went to Wuhan to inspect and direct prevention and control of COVID-19 on January 27. Premier Li, who headed the leading group, also went to Wuhan to inspect the front lines.
In meetings with the CPC's senior leaders in early February, Xi called for measures to implement higher admission and treatment rates and lower infection and fatality rates. He also asked governments at all levels to implement targeted policies to contain the outbreak quickly.
Official data showed that many provinces started to lower their major public health emergency response levels from February 21, indicating the COVID-19 outbreak was coming under control.
On March 11, daily new domestic cases fell to single digits for the first time on the Chinese mainland. A week later, the mainland reported no increase in domestic cases for the first time.
As China declared an early victory in the containment of COVID-19 and normalized epidemic prevention and control, the CPC's top leadership made arrangements to steadily lift the travel restrictions and open up economic activity.
On May 7, the central government issued guidelines on normalized epidemic prevention and control.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200610005922/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
